TG Therapeutics Inc. (NASDAQ:TGTX) – FBR & Co decreased their FY2016 earnings per share (EPS) estimates for TG Therapeutics in a report released on Monday. FBR & Co analyst E. White now forecasts that the firm will earn ($1.52) per share for the year, down from their previous forecast of ($1.22). FBR & Co currently has a “Buy” rating on the stock. FBR & Co also issued estimates for TG Therapeutics’ Q4 2016 earnings at ($0.40) EPS, FY2017 earnings at ($1.34) EPS and FY2018 earnings at ($1.60) EPS.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by $0.19. TG Therapeutics had a negative return on equity of 75.52% and a negative net margin of 47,494.08%.

Earnings History and Estimates for TG Therapeutics (NASDAQ:TGTX)

A number of other analysts have also recently commented on the stock. Zacks Investment Research cut shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday. Roth Capital restated a “buy” rating and set a $33.00 price target on shares of TG Therapeutics in a research note on Tuesday. HC Wainwright restated a “buy” rating and set a $18.00 price target (down from $22.00) on shares of TG Therapeutics in a research note on Saturday, October 15th. Ladenburg Thalmann restated a “buy” rating and set a $28.00 price target on shares of TG Therapeutics in a research note on Saturday, October 15th. Finally, Brean Capital reiterated a “buy” rating and issued a $28.00 target price on shares of TG Therapeutics in a research note on Thursday, October 6th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $20.86.

TG Therapeutics (NASDAQ:TGTX) opened at 5.60 on Wednesday. TG Therapeutics has a one year low of $4.90 and a one year high of $14.87. The firm’s market cap is $304.95 million. The stock’s 50 day moving average is $6.76 and its 200-day moving average is $6.87.

A number of hedge funds have recently bought and sold shares of the company. BlackRock Advisors LLC boosted its stake in TG Therapeutics by 14.5% in the second quarter. BlackRock Advisors LLC now owns 18,131 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 2,296 shares in the last quarter. Vanguard Group Inc. boosted its stake in TG Therapeutics by 11.5% in the second quarter. Vanguard Group Inc. now owns 1,484,133 shares of the biopharmaceutical company’s stock valued at $8,995,000 after buying an additional 152,700 shares in the last quarter. SECOR Capital Advisors LP purchased a new stake in TG Therapeutics during the second quarter valued at about $187,000. Nationwide Fund Advisors boosted its stake in TG Therapeutics by 387.7% in the second quarter. Nationwide Fund Advisors now owns 108,904 shares of the biopharmaceutical company’s stock valued at $660,000 after buying an additional 86,573 shares in the last quarter. Finally, Oxford Asset Management purchased a new stake in TG Therapeutics during the second quarter valued at about $475,000. Institutional investors and hedge funds own 54.63% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.

5 Day Chart for NASDAQ:TGTX

Receive News & Stock Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related stocks with our FREE daily email newsletter.